Viking Therapeutics(US:VKTX) Seeking Alpha·2026-01-13 06:35Company Overview - Viking Therapeutics is based in San Diego and focuses on novel therapeutics for metabolic and endocrine diseases [3]. Key Programs - The company is primarily concentrating on its metabolic disease programs, particularly a peptide called VK2735, which is a dual agonist of the GLP-1 and GIP receptors, currently in a Phase III program known as the VANQUISH program [3]. - An oral formulation of VK2735 has completed a Phase II study, with data submission planned for the European Congress on Obesity in the second quarter of this year [4]. - Viking Therapeutics is also developing an amylin program, with plans to file an Investigational New Drug (IND) application later this quarter [4]. Additional Programs - The company has earlier stage programs in the thyroid receptor space, including VK2809, a thyroid receptor beta agonist for MASH, which has completed a successful study [5].